Share on LinkedInShare on LinkedIn

ARTICLE · 31 JANUARY 2023

An Interview With Rachel Goode, Ph.D, About Biological Patent Thickets

Kevin DeJong (Senior Editor) and Shweta Kumar (Editor) from the Big Molecule Watch recently interviewed Rachel Goode, Ph.D. to discuss an article she recently co-authored...

GlobalIntellectual Property

Kevin DeJong (Senior Editor) and Shweta Kumar (Editor) from the Big Molecule Watch recently interviewed Rachel Goode, Ph.D. to discuss an article she recently co-authored, "Biological patent thickets and delayed access to biosimilars, an American problem."1 The article, published in the Journal of Law and the Biosciences, examines whether patent thickets covering biological drugs are responsible for delayed biosimilar market entry.

Dr. Goode currently serves as Senior Vice President of Legal and Intellectual Property, Biosimilars at Fresenius Kabi, a global health care and pharmaceutical company. The views expressed herein do not necessarily reflect the views or policies of Goodwin or the Big Molecule Watch, and do not necessarily reflect the official policy or position of Fresenius Kabi.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from